UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Follow-Up Questions
Quel est le ratio P/E de Ucb SA (UCBJY) ?
Le ratio P/E de Ucb SA est de N/A
Qui est le CEO de Ucb SA ?
Mr. Jean-Christophe Tellier est le Chief Executive Officer de Ucb SA, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action UCBJY ?
Le prix actuel de UCBJY est de 120.04, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Ucb SA ?
Ucb SA appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Ucb SA ?
La capitalisation boursière actuelle de Ucb SA est de $45.6
Est-ce que Ucb SA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 24 analystes ont établi des notations d'analystes pour Ucb SA, y compris 3 achat fort, 18 achat, 4 maintien, 0 vente et 3 vente forte
